Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study: reply
Rheumatology (Oxford)
.
2023 Sep 1;62(9):e278-e279.
doi: 10.1093/rheumatology/kead037.
Authors
Masaru Kato
1
,
Keita Ninagawa
1
,
Tatsuya Atsumi
1
Affiliation
1
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
PMID:
36707999
DOI:
10.1093/rheumatology/kead037
No abstract available
Publication types
Letter
Comment
MeSH terms
Cardiomyopathies* / drug therapy
Cardiomyopathies* / etiology
Humans
Lung Diseases, Interstitial*
Pilot Projects
Scleroderma, Systemic* / complications
Scleroderma, Systemic* / drug therapy
Substances
nintedanib